With increasing evidence for microbial involvement in many human diseases, live biotherapeutic products (LBPs)—living microbes administered therapeutically—have emerged as a group of exciting new drug candidates. Although the LBP regulatory environment remains uncertain, companies all […]
Following Biofortis first paper The human microbiome: a global overview of clinical trials activity, this article compares the emergence of the human microbiome field with the rise of human genomics through a review on how […]
While“healthy” microbiome remains to be defined, microbiome disruption is associated with numerous diseases, offering new therapeutic opportunities if causalities are demonstrated. Europe is at the forefront of the understanding of the Microbiome and is well placed […]